GlaxoSmithKline: Making an impact on emerging markets

Authored by Abbas Hussain, Senior Partner, C-Bridge Capital

Criticaleye recently caught up with Abbas Hussain, President, Emerging Markets at GlaxoSmithKline, to discuss the state of  emerging markets and the initial stages of GSK’s low-cost drug plan, a revolutionary scheme set to change the face of the pharmaceutical industry.

Share this with your Community





Click here to download this insight

DOWNLOAD INSIGHT



Related Insights

Read, watch & listen to some of the latest thought leadership from our Community.


Mike Maudsley, CEO of enfinium: How Great CEOs Stay Ahead of the Curve

Mike Maudsley, CEO of enfinium, joins Bridgette Hall, Senior Editor at Criticaleye, to explore what it takes to succeed as a CEO in today’s fast-changing business environment. As organisations navigate incr...


Click here to download this insight

Employee Happiness in the Age of AI

In this report, AlixPartners and Darwin X argue that retail consistently trails other industries on employee happiness, and that closing that gap is not just a people issue, but a prerequisite for competing in the ag...


The Future of Executive Leadership and High Performance

Andrew Darfoor, SID, Post Office & Board Mentor at Criticaleye, and Jodene Young, Chief People Officer at the National Physical Laboratory (NPL), join Bridgette Hall, Senior Editor at Criticaleye, for a discussio...


1 2 3 4 5 6 7 8 9 10
Displaying 1 to 3 of 198




Drax Group plc E.ON UK NATS British Land Legal & General Aldermore Group Hitachi Solutions Mayborn Group London Stock Exchange Group CrowdStrike GlaxoSmithKline plc Global Payments AlixPartners Lightsource bp Southern Water Rolls-Royce Stream LACE Partners Canaccord Genuity Group Inc NatWest Group